Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–85. https://doi.org/10.1182/blood-2004-09-3502.
Article CAS PubMed Google Scholar
Dobos G, Pohrt A, Ram-Wolff C, Lebbé C, Bouaziz JD, Battistella M, et al. Epidemiology of cutaneous T-cell lymphomas: a systematic review and meta-analysis of 16,953 patients. Cancers (Basel). 2020;12(10):2921. https://doi.org/10.3390/cancers12102921.
Article CAS PubMed Central Google Scholar
Kaufman AE, Patel K, Goyal K, O’Leary D, Rubin N, Pearson D, et al. Mycosis fungoides: developments in incidence, treatment and survival. J Eur Acad Dermatol Venereol. 2020;34(10):2288–94. https://doi.org/10.1111/jdv.16325.
Article CAS PubMed PubMed Central Google Scholar
Maguire A, Puelles J, Raboisson P, Chavda R, Gabriel S, Thornton S. Early-stage mycosis fungoides: epidemiology and prognosis. Acta Derm Venereol. 2020;100(1):adv00013. https://doi.org/10.2340/00015555-3367.
Ottevanger R, de Bruin DT, Willemze R, Jansen PM, Bekkenk MW, de Haas ERM, et al. Incidence of mycosis fungoides and Sezary syndrome in the Netherlands between 2000 and 2020. Br J Dermatol. 2021;185(2):434–5. https://doi.org/10.1111/bjd.20048.
Article CAS PubMed PubMed Central Google Scholar
Larocca C, Kupper T. Mycosis fungoides and Sezary syndrome: an update. Hematol Oncol Clin N Am. 2019;33(1):103–20. https://doi.org/10.1016/j.hoc.2018.09.001.
Scarisbrick J. Staging of mycosis fungoides and Sézary syndrome: time for an update? EMJ Allergy Immunol. 2018;6(1):92–100.
Olsen E, Whittaker S, Willemze R, Pinter-Brown L, Foss F, Geskin L, et al. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from ISCL, USCLC, and EORTC. Blood. 2022;140(5):419–37. https://doi.org/10.1182/blood-2007-03-055749.
Article CAS PubMed Google Scholar
Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28(31):4730–9. https://doi.org/10.1200/JCO.2009.27.7665.
Demierre MF, Gan S, Jones J, Miller DR. Significant impact of cutaneous T-cell lymphoma on patients’ quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey. Cancer. 2006;107(10):2504–11. https://doi.org/10.1002/cncr.22252.
Molloy K, Jonak C, Woei AJF, Guenova E, Busschots AM, Bervoets A, et al. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sezary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. Br J Dermatol. 2020;182(3):770–9. https://doi.org/10.1111/bjd.18089.
Article CAS PubMed Google Scholar
Russomanno K, Carver DeKlotz CM. Acceleration of cutaneous T-cell lymphoma following dupilumab administration. JAAD Case Rep. 2021;8:83–5. https://doi.org/10.1016/j.jdcr.2020.12.010.
Hollins LC, Wirth P, Fulchiero GJ Jr, Foulke GT. Long-standing dermatitis treated with dupilumab with subsequent progression to cutaneous T-cell lymphoma. Cutis. 2020;106(2):E8–11. https://doi.org/10.12788/cutis.0074.
Martinez-Escala ME, Posligua AL, Wickless H, Rutherford A, Sable KA, Rubio-Gonzalez B, et al. Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor-alpha therapy. J Am Acad Dermatol. 2018;78(6):1068–76. https://doi.org/10.1016/j.jaad.2017.12.068.
Article PubMed PubMed Central Google Scholar
Amitay-Laish I, Guenova E, Ortiz-Romero PL, Vico-Alonso C, Rozati S, Geskin LJ, et al. The course of mycosis fungoides under cytokine pathway blockers: a multicentre analysis of real-life clinical data. Acta Derm Venereol. 2020;100(16):adv00277. https://doi.org/10.2340/00015555-3642.
Hoot JW, Wang L, Kho T, Akilov OE. The effect of phototherapy on progression to tumors in patients with patch and plaque stage of mycosis fungoides. J Dermatol Treat. 2018;29(3):272–6. https://doi.org/10.1080/09546634.2017.1365113.
van Doorn R, Van Haselen CW, van Voorst Vader PC, Geerts ML, Heule F, de Rie M, et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol. 2000;136(4):504–10. https://doi.org/10.1001/archderm.136.4.504.
Pavlotsky F, Hodak E, Dawood M, Barzilai A. Stage IA mycosis fungoides should be treated until proven otherwise. J Am Acad Dermatol. 2020;82(1):e19–20. https://doi.org/10.1016/j.jaad.2019.09.001.
Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome—update 2017. Eur J Cancer. 2017;77:57–74. https://doi.org/10.1016/j.ejca.2017.02.027.
Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M, Committee EG. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv30–40. https://doi.org/10.1093/annonc/mdy133.
Article CAS PubMed Google Scholar
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Primary Cutaneous Lymphomas. Version 2.2021. 2020. https://www.nccn.org/professionals/physician_gls/pdf/primary_cutaneous.pdf. Accessed 28 July, 2021.
Quaglino P, Prince HM, Cowan R, Vermeer M, Papadavid E, Bagot M, et al. Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. Br J Dermatol. 2021;184(4):722–30. https://doi.org/10.1111/bjd.19252.
Article CAS PubMed PubMed Central Google Scholar
Hodak E, Amitay-Laish I. Mycosis fungoides: a great imitator. Clin Dermatol. 2019;37(3):255–67. https://doi.org/10.1016/j.clindermatol.2019.01.004.
Pimpinelli N, Olsen EA, Santucci M, Vonderheid E, Haeffner AC, Stevens S, et al. Defining early mycosis fungoides. J Am Acad Dermatol. 2005;53(6):1053–63. https://doi.org/10.1016/j.jaad.2005.08.057.
Scarisbrick JJ, Quaglino P, Prince HM, Papadavid E, Hodak E, Bagot M, et al. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol. 2019;181(2):350–7. https://doi.org/10.1111/bjd.17258.
Article CAS PubMed Google Scholar
Santucci M, Biggeri A, Feller AC, Burg G, For the European Organization for Research, Treatment of Cancer Cutaneous Lymphoma Project Group. Accuracy, concordance, and reproducibility of histologic diagnosis in cutaneous t-cell lymphoma: An EORTC Cutaneous Lymphoma Project Group study. Arch Dermatol. 2000;136(4):497–502. https://doi.org/10.1001/archderm.136.4.497.
Article CAS PubMed Google Scholar
Furlan FC, Sanches JA. Hypopigmented mycosis fungoides: a review of its clinical features and pathophysiology. Bras Dermatol. 2013;88(6):954–60. https://doi.org/10.1590/abd1806-4841.20132336.
Keehn CA, Belongie IP, Shistik G, Fenske NA, Glass LF. The diagnosis, staging, and treatment options for mycosis fungoides. Cancer Control. 2007;14(2):102–11. https://doi.org/10.1177/107327480701400203.
Chairatchaneeboon M, Thanomkitti K, Kim EJ. Parapsoriasis—a diagnosis with an identity crisis: a narrative review. Dermatol Ther. 2022. https://doi.org/10.1007/s13555-022-00716-y.
Vakeva L, Sarna S, Vaalasti A, Pukkala E, Kariniemi AL, Ranki A. A retrospective study of the probability of the evolution of parapsoriasis en plaques into mycosis fungoides. Acta Dermatovenereol. 2005;85(4):318–23. https://doi.org/10.1080/00015550510030087.
Burg G, Dummer R, Nestle FO, Doebbeling U, Haeffner A. Cutaneous lymphomas consist of a spectrum of nosologically different entities including mycosis fungoides and small plaque parapsoriasis. Arch Dermatol. 1996;132(5):567–72.
Article CAS PubMed Google Scholar
Belousova IE, Vanecek T, Samtsov AV, Michal M, Kazakov DV. A patient with clinicopathologic features of small plaque parapsoriasis presenting later with plaque-stage mycosis fungoides: report of a case and comparative retrospective study of 27 cases of “nonprogressive” small plaque parapsoriasis. J Am Acad Dermatol. 2008;59(3):474–82. https://doi.org/10.1016/j.jaad.2008.05.028.
Guitart J, Kennedy J, Ronan S, Chmiel JS, Hsiegh YC, Variakojis D. Histologic criteria for the diagnosis of mycosis fungoides: proposal for a grading system to standardize pathology reporting. J Cutan Pathol. 2001;28(4):174–83. https://doi.org/10.1034/j.1600-0560.2001.028004174.x.
Article CAS PubMed Google Scholar
Zackheim HS, McCalmont TH. Mycosis fungoides: the great imitator. J Am Acad Dermatol. 2002;47(6):914–8. https://doi.org/10.1067/mjd.2002.124696.
Song SX, Willemze R, Swerdlow SH, Kinney MC, Said JW. Mycosis fungoides: report of the 2011 Society for Hematopathology/European Association for Haematopathology workshop. Am J Clin Pathol. 2013;139(4):466–90. https://doi.org/10.1309/AJCPOBDP2OQAJ5BR.
Article CAS PubMed Google Scholar
Alsayyah A. Is it mycosis fungoides? A comprehensive guide to reaching the diagnosis and avoiding common pitfalls. Ann Diagn Pathol. 2020;47: 151546. https://doi.org/10.1016/j.anndiagpath.2020.151546.
Virmani P, Myskowski PL, Pulitzer M. Unusual variants of mycosis fungoides. Diagn Histopathol (Oxf). 2016;22(4):142–51. https://doi.org/10.1016/j.mpdhp.2016.04.004.
Article PubMed PubMed Central Google Scholar
Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703–14. https://doi.org/10.1182/blood-2018-11-881268.
留言 (0)